Loading
KT
Kalytera Therapeutics, Inc. Stock: price and insider trades · Canada
Kalytera Therapeutics, Inc.: what insiders have been doing
Insider filings for Kalytera Therapeutics, Inc. are scarce in the SEDI feed, the latest one published on 18 September 2019. This page will fill in as new trades are disclosed. These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.
Insider Decl.
7
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 18 September 2019
Declarations7 total
1,972,950 shares@ CA$0.05100.0% of flowCommon SharesTSXSEDI:3426324
526,120 shares@ CA$0.05100.0% of flowCommon SharesTSXSEDI:3426329
Common SharesTSXSEDI:3426323
771,909 sharesCommon SharesTSXSEDI:2940335
3,813,229 sharesCommon SharesTSXSEDI:2940411
Common SharesTSXSEDI:2940410
Common SharesTSXSEDI:2940332
7 of 7 declarations
About Kalytera Therapeutics, Inc.
Kalytera Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for serious diseases. It is listed on the Toronto Stock Exchange under the symbol XTSE.
